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Objective: to evaluate the effects of trolamine in the prevention or treatment of radiation 
dermatitis. Method: systematic review and meta-analysis. Detailed individual search strategies 
for Cinahl, Cochrane Library Central, LILACS, PubMed, and Web of Science were developed in 
January 2016. A manual search was also performed to find additional references. A grey literature 
search was executed by using Google Scholar. Two researchers independently read the titles and 
abstracts from every cross-reference. The risk of bias of the included studies was analyzed by 
the Cochrane Collaboration Risk of Bias Tool. The quality of evidence and grading of strength of 
recommendations was assessed using Grades of Recommendation, Assessment, Development 
and Evaluation (GRADE). Results: seven controlled clinical trials were identified. The controls 
used were calendula, placebo, institutional preference / usual care, Aquaphor®, RadiaCare™, 
and Lipiderm™. The studies were pooled using frequency of events and risk ratio with 95% 
confidence intervals, in subgroups according to radiation dermatitis graduation. Conclusion: 
based on the studies included in this review, trolamine cannot be considered as a standardized 
product to prevent or treat radiation dermatitis in patients with breast and head and neck cancer.
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Introduction
The most common effect of radiotherapy is radiation 
dermatitis, which has greater impact in patients with 
head and neck and breast cancer(1). About 80 to 90% 
of these patients treated by radiotherapy experience 
radiation dermatitis during treatment(2-3).
The skin is an organ with high radiosensitivity and 
susceptible to damage by radiotherapy due to rapid 
cell proliferation and maturation. The epidermis loses a 
percentage of its basal cell exposure beginning at the 
first fractionated dose of radiotherapy, and the repeated 
exposure of the subsequent fractions leads to continuous 
cell destruction, which avoids tissue repair(4).
Although the skin damage starts after the first 
exposure to radiation, the clinical signs are often 
present from the second week of radiotherapy. They 
are characterized by mild erythema, which can develop 
to dry or moist desquamation, and ulcerations in some 
cases(5-6).
Acute skin reactions generate local discomfort, 
itching and varied degrees of pain that impact the quality 
of life of patients and affect the therapeutic efficacy and 
the planning of radiotherapy, considering that severe 
intensity lesions can cause interruption of treatment(1,7).
Trolamine has been indicated to prevent and treat 
radiation dermatitis but, to the best of our knowledge, 
there is no systematic review that evaluated trolamine 
as a potential topical product to manage skin reactions 
due to radiotherapy.
Background
Skin reactions may be intensified, according to 
the treatment plan received, a full high dose, fractional 
high dose, and the extension of the irradiated area. 
Chemotherapy and patient related factors, such as age, 
skin color, smoking habits and obesity also aggravate 
the skin reactions(6,8).
Topical products are commonly used as alternatives 
to manage skin reactions due to radiotherapy, although 
there is insufficient evidence regarding skin care 
products for the prevention or treatment of radiation 
dermatitis(6).
Topical application of emulsions containing 
trolamine has bee used in clinical practice for more 
than three decades in Europe and in the United States 
for the management of radiation dermatitis. Trolamine 
has the capacity to heal through the recruitment of 
macrophages to the wound, promoting the growth of 
granulation tissue(9). Trolamine emulsion is a compound 
with properties similar to nonsteroidal anti-inflammatory 
agents and has been considered as a safe and tolerable 
topical intervention, with low potential to develop 
contact dermatitis. Trolamine promotes skin hydration 
and reduces discomfort and pain, which contribute to 
the non-interruption of treatment(9).
The evidence and clinical observations demonstrate 
the advantages and disadvantages between trolamine 
and other topical products, including steroidal creams, 
non-steroidal anti-inflammatory compounds, and 
antihistamines(1,10).
The aim of this study is to systematically review the 
literature about the evidence of trolamine compared to 
other topical products in the prevention and treatment 
of acute radiation dermatitis in cancer patients.
Method
Protocol and registration
The reporting of this systematic review adhered to 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses PRISMA Checklist(11). The systematic 
review protocol was registered at the International 
Prospective Register of Systematic Reviews (PROSPERO), 
registration number CRD42016032805(12).
Eligibility criteria
Only original prospective studies in which the 
objective was to investigate the effects of the use 
of trolamine as the only active ingredient (without 
associations) to prevent and treat acute radiation 
dermatitis compared to other topical products in cancer 
patients undergoing radiotherapy were eligible. Studies 
published in Portuguese, English, Spanish, and French 
were included. There were no restrictions to the year of 
publication. The age of the participants, sex, previous 
or concurrent therapies, health status or dosage of 
treatment was not restricted either.
Studies were excluded for the following reasons: 1. 
cobalt therapy; 2. studies that compared interventions to 
chronic radiation dermatitis only; 3. trolamine associated 
with others compounds; 4. trolamine compared with 
non-topical products; 5. study design: reviews, letters, 
conference abstracts, personal opinions, book chapter, 
retrospective study, descriptive study, case reports or 
case series.
Information sources and search strategy
Studies were identified using a search strategy 
adapted for each electronic database, with the aid of 
a health sciences librarian: CINAHL EBSCO, Cochrane 
Central Register of Controlled Trials (CENTRAL), LILACS, 
PubMed, and Web of Science. The hand search was 
performed on the reference lists from the selected 
articles for any additional references that might have 
been missed in the electronic search. In addition, a grey 
literature search was performed using Google Scholar.
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We used the following search terms to search 
PubMed and adapted the strategy for the other databases: 
(“biafine” OR “triethanolamine” OR “trolamine” OR 
“trolamine emulsion” OR “emulsion containing trolamine”) 
AND (“radiodermatitis” OR “dermatitis” OR “radiation 
dermatitis” OR “radio-dermatitis” OR “skin damage” OR 
“skin toxicity” OR “skin reaction” OR “skin injuries” OR 
“radiation reaction” OR “radio-epithelitis” OR “acute skin 
toxicity” OR “acute skin reaction” OR “acute dermatitis” 
OR “acute radiodermatitis” OR “acute cutaneous toxicity” 
OR “acute radiation dermatitis” OR “acute radiation 
reactions” OR “acute radiation-induced skin reactions” 
OR “radiation-induced acute skin” OR “radiation induced 
skin injuries” OR “radiation-induced skin reaction” OR 
“radiation induced dermatitis” OR “radio-induced damage” 
OR “radiotherapy-induced skin reactions” OR “radiation 
skin reactions” OR “radiation-induced skin injuries”).
After obtaining all references, duplicates were 
excluded by using appropriate software (EndNoteBasic®, 
Thomson Reuters, USA). All the electronic database 
searches were undertaken on January 18th, 2016.
Study selection
For the phase of screening and data extraction, 
©Covidence (Web-based systematic review tool 
designed to facilitate the process) was used.
The study selection was conducted in two phases. In 
phase 1, two investigators (A.G.M. and E.B.F.) independently 
screened the titles and abstracts of potentially relevant 
studies and selected articles that appeared to meet the 
inclusion criteria based on their abstracts. In phase 2, 
the same reviewers independently read the full-text of all 
selected articles and excluded studies that did not meet 
the inclusion criteria. Any disagreements, either in the 
first or second phases, were resolved by discussion and 
mutual agreement between the two reviewers. In case a 
consensus could not be reached, a third author (P.E.D.R.) 
was involved to make a final decision. Studies that were 
excluded after full-text assessment and the reasons for 
their exclusion are listed in Figure 1.
Data collection process and items
Two investigators (A.G.M. and E.B.F.) independently 
collected the data from the selected articles: study 
characteristics (author(s), year of publication, setting, 
objectives, methods), population characteristics (sample 
size, age, irradiated area), intervention characteristics 
(groups, follow-up period, primary outcomes, radiation 
dermatitis criteria and statistical analysis), and outcome 
characteristics (main results). The third author (P.E.D.R.) 
crosschecked all the retrieved information to make a 
final decision. If the required data were not complete, 
attempts were made to contact the authors to retrieve 
any pertinent missing information.
Risk of bias in individual studies
To assess the risk of bias of the included 
randomized controlled trials (RCT), the Cochrane 
Collaboration Risk of Bias Tool(13) was applied, including 
judgments about the sequence generation, allocation 
concealment, blinding of participants, personnel and 
outcome assessors, incomplete outcome data, selective 
reporting, and other sources of bias. The risk of bias 
was assessed as low, high or unclear. Two investigators 
performed this process independently (A.G.M. and 
E.B.F.). Disagreements between the 2 reviewers were 
resolved by a third investigator (P.E.D.R.).
Summary measures
The primary outcome was the development of 
different grades of radiation dermatitis or the reduction 
of the intensity/degree of reaction. Further measures 
considered in this review were risk ratio (RR) or risk 
differences for dichotomous outcomes.
Synthesis of results
The overall data combination of the included 
studies was performed by a descriptive synthesis. 
Statistical pooling of data using meta-analysis was 
planned whenever trials were considered combinable 
and relatively homogeneous in relation to design, 
interventions and outcomes. Heterogeneity within 
studies was evaluated either by considering clinical 
(differences about participants, type of controls and 
results), methodological (design and risk of bias) 
and statistical (effect of studies) characteristics or by 
using the I2 statistical test. A value from 0 to 40% 
was considered of not important consistency, between 
30 and 60% moderate heterogeneity, whereas 50 
to 90% was considered to represent substantial 
heterogeneity(13).
The Cochrane Collaboration´s Review Manager® 5 
(RevMan 5) was used to summarize the results by 
means of the Mantel-Haenszel model. The results were 
presented with 95% confidence intervals (95% CI).
Risk of bias across studies
The quality of evidence and grading of the strength 
of recommendations was assessed using the Grades 
of Recommendation, Assessment, Development and 
Evaluation (GRADE)(14-15). The criteria for this assessment 
were study design, risk of bias, inconsistency, indirectness, 
imprecision and other considerations. The quality of 
evidence must be characterized as high, moderate, low, 
or very low(15).
No funnel plot was constructed to assess the 
possibility of publication bias because there were few 
trials per subgroups of meta-analysis.
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Results
Study Selection
In phase 1 of study selection, 195 citations 
were identified across five electronic databases. After 
the duplicated articles were removed, 138 citations 
remained. No references from grey literature were 
added. A thorough screening of the titles and abstracts 
was completed and 126 references were excluded. A 
manual search from the reference lists of the identified 
studies yielded no additional studies. Thus, 12 articles 
remained for a full-text screening (phase 2). This process 
led to the exclusion of five studies (Figure 1). In total, 
seven articles(16-22) were selected for data extraction 
and qualitative synthesis (Figure 2). Figure 1 (flow 
chart) details the process of identification, inclusion and 
exclusion of studies with reasons.
Figure 1 – Flow diagram of literature search and selection process. Brasília, DF, Brazil, 2016
Study characteristics
The studies were published in English(16-19,21-22) and 
French(20), from 2000 to 2012.
Two studies included patients who also underwent 
concurrent chemotherapy(19,22). Radical radiotherapy 
has been reported in five studies(16-18,20-21). The use of 
tamoxifen has been described in only one study, among 
those including patients with breast cancer(17).
Two studies(19,22) included only head and neck 
cancer patients, and four studies(16-18,21) included only 
breast cancer patients in the sample. Only one(20) of 
the selected studies included a heterogeneous sample 
of patients with different cancer types and irradiated 
areas: breast and head and neck cancer.
All studies evaluated trolamine as an intervention 
to prevent radiation dermatitis and only one evaluated 
trolamine as treatment(19). The topical controls were 
usual care/institution routine(16,19,22), calendula(18), water 
thermal gel(20), placebo, Aquaphor®, RadiaCare™(21), 
Lipiderm and no intervention(17).
Table 1 summarizes the descriptive characteristics 
of the studies.
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Risk of bias within studies
The risk of bias was analyzed individually in all 
studies included. One randomized clinical trial was 
graded as having a low risk of bias in the six domains 
assessed(21) (Figure 2). Four studies(16,19-20,22) exhibited an 
unclear risk of selection bias due to the poor description 
of the randomization strategy. One of the studies(17) had 
a high risk of bias due to randomization description of 
the inclusion of participants in the intervention groups 
consecutively. The domain “selective reporting” showed 
predominantly low risk of bias in the evaluation of the 
studies (100%).
Four studies were classified as high risk of bias 
because they contained one or more compromised 
domains(16-17,19-20). Two studies were classified as 
uncertain risk of bias(18,22). One of them received 
positive bias ratings, with low risk of bias in 91% of 
the evaluated domains(18). Only one study presented 
low risk of bias in all domains evaluated(21), allowing 
us to ascribe the results of the study as of increased 
reliability.
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Figure 2 – Risk of bias assessment for individual studies. Brasília, DF, Brazil, 2016.
Results of individual studies
The studies used trolamine to prevent or treat 
radiation dermatitis and reported different results for 
all 7 articles. Characteristics and results of the included 
studies are listed in Table 1.
Synthesis of results
Regarding the rating scales, five studies used 
exclusively the RTOG scale (71.4%)(16-18,21-22), one of 
them used only NCI-CTC (14,1%)(20), and one study 
used both NCI-CTC and ONS scales to assess the skin 
reactions of their patients(19).
The studies were grouped into subgroups according 
to the graduation of radiation dermatitis(16,18-22). Overall, 
the results of this random-effect meta-analysis 
demonstrate that there is no difference between the use 
of trolamine and evaluated controls to prevent radiation 
dermatitis (RR 1.02, 95% CI: 0.92 – 1.14. I2 = 49%) 
(Figure 3).
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0.1%
1.9%
0.2%
7.6%
15
159
74
126
30
404
0.38 [0.12, 1.15]
1.10 [0.72, 1.70]
0.22 [0.01, 4.58]
2.19 [1.04, 4.62]
2.07 [0.20, 21.60]
1.05 [0.54, 2.06]
163
66
29
258
90
24
8
122
159
74
30
263
9.1%
4.3%
1.8%
15.1%
31
43
14
88
163
66
29
258
159
74
30
263
4.1%
6.4%
2.5%
13.0%
0.94 [0.60, 1.48]
0.86 [0.63, 1.17]
0.74 [0.39, 1.39]
0.86 [0.68, 1.09]
0.95 [0.78, 1.16]
1.26 [0.81, 1.96]
1.29 [0.59, 2.81]
1.01 [0.85, 1.21]
15
163
66
29
273
0
2
5
7
14
15
159
74
30
278
Not estimable
2.44 [0.48, 12.39]
1.35 [0.43, 4.20]
1.03 [0.41, 2.58]
1.30 [0.67, 249]
0.5%
0.9%
1.3%
2.7%
Trolamine Control Risk Ratio
Events Total Events Total Weight M-H, Random, 95%CI
Risk Ratio
M-H, Random, 95%CI
2.1.6 Grade 0-1
Elliott et al. 2006
Fisher et al. 2000
Pommier et al. 2004
Ribet et al. 2008
Subtotal (95% CI)
Total events
Heterogeneity: Tau2 = 0.02; Chi2 = 5.61, df = 3 (P = 0.09); I2 = 47%
Test for overall effect: Z = 1.77 (P = 0.08)
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Figure 3 – Forest plot of trolamine vs. controls according to the degree of radiation dermatitis
Risk of bias across studies
The quality of the evidence from the outcomes 
evaluated by the GRADE system was assessed as very low 
(Figure 4), suggesting very low confidence in the estimated 
effect based on the outcomes assessed. It means that the 
true effect is likely to be substantially different from the 
estimate of effect. The important limitations in the studies 
and inconsistency were the main factors responsible for 
the low quality of the evidence from the studies evaluated.
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Discussion
In this review, seven studies evaluating trolamine 
to prevent or treat radiation dermatitis were included. 
In four studies(17-19,21), no benefits were shown for the 
use of trolamine to prevent radiation dermatitis and, 
in two studies(16,20) there was no difference to prevent 
radiation dermatitis between trolamine and evaluated 
controls. Only one study(22) showed satisfactory use 
of trolamine in the prevention of radiation dermatitis, 
but its results showed benefit only to prevent grade 3 
radiation dermatitis.
Trolamine has been considered because of its good 
tolerability and its ability to moisturize skin and reduce 
local discomfort. However, it has not been proven that 
trolamine is a topical skin radioprotective agent(9). Some 
controls presented greater or similar efficacy when 
compared to trolamine(16-21). According to the meta-
analysis, there is no difference between trolamine and 
controls to prevent radiation dermatitis(16,18-22).
The skin moisture and the skin reactions from 
the radiotherapy could be influenced by the number of 
intervention applications along the day. Some studies 
instructed the patients to apply the intervention three 
times a day(16,19,22) or twice daily(17,21) or five times 
a day(20). Only one study(18) allowed patients to apply 
the intervention twice a day or more according to the 
frequence of radiation dermatitis and pain. None of 
this studies described a relation between the frequence 
of intervention and control applications and the skin 
moisture. One of the studies(17) asked patients to start 
the product application ten days before the onset of 
radiotherapy, but no contribution was added to prevent 
radiation dermatitis.
The product quantity in each application was not 
measured by the studies, except in one of the studies(18) 
in which the mean total number of tubes was 1.62 times 
more used in the trolamine group than in the calendula 
group.
Patients considered trolamine use more satisfactory 
than controls when compared to calendula(18) and 
AquaphorR and RadiaCareR(21).
Some studies have shown that chemotherapy and 
tamoxifen increased the intensity of skin reactions in 
patients undergoing radiotherapy(23-26). Two studies used 
chemoradiotherapy(19,22) and, in one study, tamoxifen 
was used concomitantly with radiotherapy in breast 
cancer patients(17), but these studies did not report 
significant differences in the skin reactions between the 
groups using trolamine or controls.
Only one study evaluated the efficacy of trolamine 
to treat radiation dermatitis, and considered no efficacy 
of trolamine in head and neck cancer patients(19). It is 
important that other studies evaluate trolamine to treat 
grade 1 and grade 2 radiation dermatitis, because these 
grades require products with moisturizing and anti-
inflammatory action. One of the studies(22) considered 
that trolamine prevents grade 3 of radiation dermatitis 
in head and neck cancer patients, but this conclusion 
is only based on those patients who did not develop 
grade 3 of radiation dermatitis. Moreover, the non-
development of maximum grades of radiation dermatitis 
depends on extrinsic (total dose, fractionation, radiation 
energy, volume of treated regions, treatment duration, 
boost aplication, and treatment site) and intrinsic factors 
(age, comorbid conditions, skin phototype, and genetic 
predisposition)(27).
Conclusion
Based on the studies included in this review, 
trolamine cannot be considered as a standardized 
product to prevent or treat radiation dermatitis in 
patients with breast and head and neck cancer. Further 
well-structured blinded studies using trolamine as a 
treatment are required to evaluated the moisturizing 
and anti-inflammatory action.
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